Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
This potential ban is being challenged by TikTok on First Amendment grounds, with the company referring to it as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback